From: Nomogram predict relapse-free survival of patients with thymic epithelial tumors after surgery
Characteristic | Training Cohort(n = 116) | Validation Cohort(n = 40) | ||
---|---|---|---|---|
N | % | N | % | |
Gender | ||||
Male | 63 | 54.3 | 20 | 50.0 |
Female | 53 | 45.7 | 20 | 50.0 |
Age (years) | ||||
≤ 60 | 89 | 76.7 | 32 | 80.0 |
>60 | 27 | 23.3 | 8 | 20.0 |
Smoking history | ||||
Never | 84 | 72.4 | 34 | 85.0 |
Ever | 32 | 27.6 | 6 | 15.0 |
Drinking history | ||||
No | 100 | 86.2 | 37 | 92.5 |
Yes | 16 | 13.8 | 3 | 7.5 |
Family history of tumor | ||||
No | 98 | 84.5 | 34 | 85.0 |
Yes | 18 | 15.5 | 6 | 15.0 |
Underlying diseases | ||||
No | 82 | 70.7 | 34 | 85.0 |
Yes | 34 | 29.3 | 6 | 15.0 |
Tumor size (cm) | ||||
≤ 6 | 65 | 56.0 | 24 | 60.0 |
>6 | 51 | 44.0 | 16 | 40.0 |
pT stage | ||||
T1 | 91 | 78.4 | 31 | 77.5 |
T2–3 | 25 | 21.6 | 9 | 22.5 |
Masaoka stage | ||||
I | 61 | 52.6 | 15 | 37.5 |
II-III | 55 | 47.4 | 25 | 62.5 |
WHO stage | ||||
A-AB | 45 | 38.8 | 18 | 45.0 |
B1-B3 | 60 | 51.7 | 17 | 42.5 |
C | 11 | 9.5 | 5 | 12.5 |
Myasthenia gravis, | ||||
No | 107 | 92.2 | 37 | 92.5 |
Yes | 9 | 7.8 | 3 | 7.5 |
tumor capsule status | ||||
Incomplete | 38 | 32.8 | 9 | 22.5 |
Complete | 78 | 67.2 | 31 | 77.5 |
Invasion of great vessels | ||||
No | 91 | 78.4 | 33 | 82.5 |
Yes | 25 | 21.6 | 7 | 17.5 |
ALB | ||||
≤ 40.8 | 29 | 25.0 | 7 | 17.5 |
>40.8 | 87 | 75.0 | 33 | 82.5 |
GLB | ||||
≤ 28.8 | 58 | 50.0 | 6 | 15.0 |
>28.8 | 58 | 50.0 | 34 | 85.0 |
A/G | ||||
≤ 1.5 | 54 | 46.6 | 18 | 45.0 |
>1.5 | 62 | 53.4 | 22 | 55.0 |
NE | ||||
≤ 5.6 | 102 | 87.9 | 32 | 80.0 |
>5.6 | 14 | 12.1 | 8 | 20.0 |
LY | ||||
≤ 2.5 | 28 | 24.1 | 8 | 20.0 |
>2.5 | 88 | 75.9 | 32 | 80.0 |
NE/LY (NLR) | ||||
≤ 3.0 | 100 | 86.2 | 32 | 80.0 |
>3.0 | 16 | 13.8 | 8 | 20.0 |
PLT | ||||
≤ 237 | 64 | 55.2 | 16 | 40.0 |
>237 | 52 | 44.8 | 24 | 60.0 |
PLT/LY (PLR) | ||||
≤ 161.6 | 104 | 89.7 | 32 | 80.0 |
>161.6 | 12 | 10.3 | 8 | 20.0 |
PLT/NE*LY (SII) | ||||
≤ 764.3 | 102 | 87.9 | 30 | 75.0 |
>764.3 | 14 | 12.1 | 10 | 25.0 |